Current Cardiac Lab Research Projects
A Prospective Multi-center Study Comparing the CYPHER ELITE and the CYPHER Bx VELOCITY® Sirolimus-Eluting Stent Systems.
The objective of this study is to show similar safety and effectiveness for the CYPHER Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for the treatment of de novo native coronary lesions. Eligible patients will be randomized to CYPHER ELITE or CYPHER Bx VELOCITY Sirilimus-Eluting Stents. All patients will be followed for 60-months for effectiveness of the new stent system.
A prospective, randomized, multi-center, trial to assess the effectiveness and safety of different duration of dual anti-platelet therapy in patients undergoing Percutaneous Coronary Intervention with the CYPHER Sirolimus-eluting coronary stent (Cypher Stent). Dual anti-platelet therapy consists of Aspirin plus a thienopyridine medication such Ticlid, Plavix ,or Effient.
During Phase I (non-randomized phase) of this study, the primary objective is to assess the rate of failure in patients implanted with the CYPHER stent in native coronary artery or coronary artery bypass graft lesions receiving dual antiplatelet therapy for 12 months.
During Phase II (randomized phase) of this study, the primary objective is to assess safety (bleeding risk), need for repeat procedures in all patients treated with dual antiplatelet therapy for 12 or 30 months following CYPHER stent implantation.
A clinical evaluation of the Medtronic Endeavor Resolute Zotarolimus-eluting coronary stent in the treatment of new narrowings in native coronary arteries.
The purpose of this study is evaluate if the new Endeavor Resolute stent using the new polymer is safe and how effective the drug-eluting stent is in reducing the renarrowing in coronary arteries over time.
THROMBIN RECEPTOR ANTAGONIST IN SECONDARY PREVENTION OF ATHEROTHROMBOTIC ISCHEMIC EVENTS. TIMI 50
A multicenter, randomized, study to evaluate the safety and efficacy of SCH 530348 (investigational medication) in addition to standard care in patients with a history of atherosclerotic disease:
The primary objective is to evaluate the hypothesis that SCH 530348 added to standard of care will reduce the incidence of atherothrombotic ischemic events relative to standard of care alone, as measured by the incidence of cardiovascular death, MI, stroke, and urgent coronary revascularization. Patients begin taking investigational treatment as soon as possible after randomized treatment assignment and continue daily for at least 1 year until the trial ends.
This multicenter, randomized, study is designed to compare the inhibition of platelet aggregation achieved with prasugrel (Effient) following clopidogrel (PLavix) versus prasugrel (Effient) alone in patients with acute coronary syndrome who are to undergo percutaneous coronary intervention.